We’ve been continuing to analyze the CMS reimbursement data that we received via our FOIA request, and for this post I analyzed the variability in the amounts at which tests were reimbursed by CMS during 2014. The net conclusion is that variability appears to be quite high.
For the four common cancer biomarkers that I analyzed (BRAF, EGFR, HER2, and KRAS), the testing was reimbursed at 25 or more different amounts. HER2 stands out dramatically in that it was reimbursed at 677 different amounts.
Please contact me if you have any specific questions that you are interested in having answered about CMS reimbursement of IVD tests, as we have a wealth of information to draw upon to help answer your questions.